DNLI News and Press, Denali Therapeutics Inc. From 12/10/25

2025-12-10 05:34:17 ET More on Denali Therapeutics Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript Denali Therapeutics Inc. (DNLI) Analyst/Investor Day - Slideshow Denali: Regulatory Delay Is A Strategic Opportunity Denali Therapeutics prices ...

2025-12-10 02:50:17 ET More on Denali Therapeutics Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript Denali Therapeutics Inc. (DNLI) Analyst/Investor Day - Slideshow Denali: Regulatory Delay Is A Strategic Opportunity Denali Therapeutics announc...

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain inves...

2025-12-09 16:16:59 ET More on Denali Therapeutics Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript Denali Therapeutics Inc. (DNLI) Analyst/Investor Day - Slideshow Denali: Regulatory Delay Is A Strategic Opportunity Denali Therapeutics gets FD...

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its comm...

2025-12-05 02:58:49 ET Denali Therapeutics Inc. (DNLI) Analyst/Investor Day December 4, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is De...

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Den...

2025-12-02 08:09:40 ET The biotech industry is generally understood to be high-risk when it comes to the development of drugs. There is, however, an intermediate stage in which the FDA is reviewing a Biopharmaceutical Company's filing that can hide the success of the underlying technolo...

2025-11-28 13:30:48 ET More on the markets Is There Something Wrong With This Rally? No, And These 7 Graphs Prove It What To Expect In December There's A Bigger Threat To Markets Unfolding Now, And It's Not AI Infrastructure Trump to halt migration from all '...